

Grants Received

2014-2019 | Complement in inflammatory diseases: Mechanisms & therapeutic modulation NIH P01-AI068730 Total Support $10,000,000 (Priority Score 1) |
2013-2017 | Disarming the intravascular innate immune response to improve modalities for chronic kidney disease treatment DIREKT (FP7-HEALTH-2013-INNOVATION-1) EUROPEAN GRANT PI: B Nilsson; Co-PI: JD Lambris Total Support for JD Lambris: $1,000,000 |
2013-2017 | Structural analysis of the third component of complement NIH AI 30040 Total Support $1,471,833 |
2012-2016 | Novel mechanisms and Complement-ary therapy in periodontitis NIH DE021685 PI: G Hajishengallis; Co-PI: JD Lambris Total Support: $2,000,000 |
2012-2015 | A novel approach for assessing dynamic events in the human complement system NIH R21-AI097805 PI: D. Ricklin; Co-PI: John D. Lambris Total Support: $676,800 |
2011-2016 | Complement inhibition as sepsis therapy NIH 1-R01-GM-097747-01 M.P.I. JD Lambris & F Lupu (University of Oklahoma) Total Support $2,084,220 |
2011-2015 | Complement in AMD: Mechanisms and therapeutic intervention NIH 5-R01-EY-020633 |
2012-2013 | Complement based therapies to periodontal disease ITMAT University of Pennsylvania UL1RR024134 |
2011-2012 | A novel iron-amyloid beta pathway for complement activation quantified with a new high sensitivity assay Beckman Foundation (Arnold and Mabel) (P.I. Dunaief, Joshua L University of Pennsylvania) |
2007-2012 | Complement in cell proliferation and injury - therapeutic interventions NIH, effort 40% Total Support $7,500,000 (Priority Score 154) |
2007-2012 | Complement mediated neuronal injury in stroke NIH (P.I.Connely, Columbia University), effort 5% Total Support for JDL $634,000. |
2007-2012 | Design of novel complement inhibitors NIH Total Support $1,260,000 (Priority Score 127, 7.7 Percentile) |
2007-2012 | Structural functional analysis of staphylococcal complement inhibitors NIH (P.I.Geisbrecht, B University of Missouri-Kansas City) Total Support for JDL $780,000 (9.9 Percentile) |
2007-2012 | Thermodynamic and structural studies on formation of the C3 convertase NIH, effort 10% Total Support $1,981,250 (2.9 Percentile) |
2006-2012 | Structural and functional analysis of C3 NIH AI 30040 Total Support $1,631,875 (2 Percentile) |
2005-2010 | Biomaterial-induced complement activation NIH Total Support $1,064,213 (12.7 Percentile) |
2005-2010 | The role of complement in ovarian cancer NIH Total Support $1,585,000 (3.6 Percentile) |
2004-2008 | Computer aided design of complement therapeutics NIH R24GM069736 Total Support $1,871,000 (Priority Score 127, 7.7 Percentile) |
2004-2007 | In Silico De Novo protein design: A Dynamically Data Driven, (DDDAS), Computational and experimental framework ITR: Collaborative Research: (ASE+NHS+EVS)-(sim+dmc+int) NSF 0426691 (P.I.Floudas, C. Princeton), effort 10% Total Support for JDL $370,000. |
2003-2007 | Defence against biowarfare and emerging infection agents. Sub project 3 of poxvirus project: Identify the targets of VIG using proteomics approach NIH U54 AI057168-01, effort 10% Total Support $720,000 |
2001-2007 | Structural-functional analysis of Compstatin NIH GM-62134 Total Support $1,300,000 (9.9 Percentile) |
2001-2006 | Vaccinia B5R protein in spread immune evasion, vaccines NIH (P.I.Isaacs, S), effort 5% Total Support for JDL $395,500 |
2000-2006 | Structural and functional analysis of C3 NIH AI 30040 Total Support $1,193,000 |
2000-2004 | Poxvirus SCR-containing proteins as therapeutic targets NIH (P.I.Isaacs, S), effort 5% Total Support for JDL $521,500 |
1999 | Purchase of a MALDI/MS system NIH Total Support $250,000 |
1998-2003 | Role of B cells in autoimmune diabetes NIH (P.I.Naji, A), effort 5% Total Support for JDL $324,320 |
1998-2003 | Studies on complement diversity and evolution NIH GM-56698, effort 10% Total Support $1,231,877 |
1997-2003 | Pathogenesis of persistent viral injury to the CNS-Sub: Early events in herpes simple virus entry into cells of neural origin NIH (P.I.Eisenberg, R), effort 5% Total Support for JDL $160,000 |
1997-2002 | Cellular interactions of plasma proteins NIH P-10-HL-56914 (P.I.Walsh, P), effort 10% Total Support for JDL $688,000 |
1997-2002 | Early events in Herpes Simplex Virus Entry NIH (P.I.Eisenberg, R), effort 5% Total Support for JDL $159,000 |
1997 | Purchase of an HPLC system Research Foundation of the University of Pennsylvania Total Support $14,500 |
1996-2001 | Virus and immune injury to vessel wall cells NIH 5 RO1 HL28220, effort 10% Total Support $625,770 |
1995-1999 | CSVTCG-Specific thrombospondin receptor in breast cancer NIH CA65675 (P.I.Tuszynski, G), effort 10% Total Support for JDL $379,624 |
1995 | Purchase of multiple peptide synthesizer Research Foundation of the University of Pennsylvania Total Support $32,000 |
1994-1997 | Structural and functional analysis of complement proteins from different species NSF MCB-9319111 Total Support $300,000 |
1993-1998 | Structural and functional analysis of C3 from different species NIH AI 30040 Total Support $1,124,199 |
1992-1995 | Peritoneal macrophage migration in endometriosis NIH HD 30475 (P.I.Coutifaris, C), effort 10% Total Support for JDL $297,241 |
1991-2002 | Support Grant University of Pennsylvania Diabetes Center 2P30-DK-19525 (P.I.Matschinsky, F), effort 10% Total Support for JDL $480,625 |
1991-1994 | Structural and functional analysis of chicken and lamprey C3 NSF DCB-9018751 Total Support $300,000 |
1991-1992 | Research Grant Research Foundation of the University of Pennsylvania URF-3-71696 Total Support $12,000 |
1990-1991 | Structural analysis of C3d/EBV-CR2 interactions American Cancer Society IN-135K Total Support $10,000 |
1989-2001 | Support Grant University of Pennsylvania Cancer Center 5P30-CA-16520 (P.I.Glick, J), effort 10% Total Support for JDL $710,000 |
1984-1987 | Research Grant NIH 1R01-AI21014 Total Support $320,000 |
1982-1984 | New Investigator Award NIH IR23-AI-18546 Total Support $180,000 |
1982 | Research Grant American Cancer Society IM-308 Total Support $140,000 |